AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

TELIX PHARMACEUTICALS LTD

18.085

+1.74510.68%

Volume:2.55M

Turnover:45.10M

Market Cap:6.13B

PE:135.25

High:18.220

Open:16.800

Low:16.700

Close:16.340

52wk High:18.320

52wk Low:8.260

Shares:338.72M

Float Shares:275.41M

Volume Ratio:7.94

T/O Rate:0.93%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.134

EPS(LYR):-0.030

ROE:7.36%

ROA:2.71%

PB:8.96

PE(LYR):-611.41

Loading ...

Overview Company News Filings

Telix Pharmaceuticals Ltd - Telix Successfully Prices Upsized US$600M Convertible Bonds

THOMSON REUTERS

Telix Pharmaceuticals Ltd - Upsizes Convertible Notes Due 2031 to US$600 Milion - SEC Filing

THOMSON REUTERS

Top Premarket Decliners

MT Newswires Live

BRIEF-Telix Pharmaceuticals Launches Offering Of $550 MLN Convertible Notes Due 2031 To Be Issued By Its Unit

Telix launches US$550 million convertible notes offering due 2031

Telix Refinances Convertible Bonds

Telix Pharmaceuticals Ltd - Launches an Offering of US$550 Mln Convertible Notes Due 2031 to Be Issued by Its Wholly-Owned Subsidiary

THOMSON REUTERS

Telix Pharmaceuticals Ltd - Initial Conversion Price Will Be at a Premium to Telix's Current Share Price.

THOMSON REUTERS

Regeneron Pharmaceuticals Inc - Telix Will Receive an Upfront Cash Payment of US$40 Mln From Regeneron

THOMSON REUTERS

BUZZ-Australia's Telix Pharmaceuticals rises on $40 mln Regeneron deal; Citi sees 'broader' scope

Stock Track | Telix Pharmaceuticals Soars 7.58% Intraday on Major Regeneron Collaboration Deal

Telix and Regeneron Announce Strategic Radiopharma Collaboration

Telix Pharmaceuticals Ltd - to Receive $40 Mln Upfront and up to $2.1 Bln in Milestones Plus Royalties

THOMSON REUTERS

Telix Pharmaceuticals Ltd-Telix and Regeneron Announce Radiopharma Collaboration

THOMSON REUTERS

Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Amid Lingering Geopolitical Uncertainty, CPI Focus

MT Newswires Live

BUZZ-Australia's Telix Pharmaceuticals rises as US FDA approves drug application

Stock Track | Telix Pharmaceuticals Soars 8.14% Intraday on FDA Acceptance of Brain Cancer Imaging Agent NDA

Telix Pharmaceuticals Says US FDA Accepts New Drug Application for Brain Cancer Imaging Agent

MT Newswires Live

FDA Accepts Nda for Tlx101-Px (Pixclara®)

THOMSON REUTERS

FDA Accepts NDA for TLX101-Px (Pixclara®)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/TLX.AU/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"TLX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","market":"AU","secType":"STK","nameCN":"TELIX PHARMACEUTICALS LTD","latestPrice":18.085,"timestamp":1789433525032,"preClose":16.34,"halted":0,"volume":2549975,"delay":0,"changeRate":0.10679314565483482,"nameEN":"TELIX PHARMACEUTICALS LTD","floatShares":275410996,"shares":338721355,"eps":0.1337153799461976,"marketStatus":"Trading","change":1.745,"latestTime":"09-15 10:52:05 AEST","open":16.8,"high":18.22,"low":16.7,"amount":45099519,"amplitude":0.093023,"askPrice":18.09,"askSize":186,"bidPrice":18.08,"bidSize":420,"shortable":3,"etf":0,"ttmEps":0.1337153799461976,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789452000000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":16.34,"openAndCloseTimeList":[[1789430400000,1789452000000]],"volumeRatio":7.940384,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"TLX.AU","preClose":16.34,"auctionPrice":16.8,"auctionVolume":65194,"auctionTime":1789430346379,"referenceTime":1789381803089,"auction":1,"marketStatus":"盘前竞价","timestamp":1789430346379}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","floatShares":275410996,"roa":"2.71%","roe":"7.36%","lyrEps":-0.029579,"volumeRatio":7.940384,"shares":338721355,"dividePrice":0,"high":18.22,"amplitude":0.093023,"preClose":16.34,"low":16.7,"week52Low":8.26,"pbRate":"8.96","psRate":"4.91","week52High":18.32,"institutionHeld":0,"latestPrice":18.085,"committee":0.386139,"eps":0.1337153799461976,"divideRate":0,"volume":2549975,"delay":0,"ttmEps":0.1337153799461976,"open":16.8,"prevYearClose":11.2,"prevWeekClose":15.67,"prevMonthClose":15.36,"prevQuarterClose":16.58,"fiveDayClose":16.5,"twentyDayClose":16.76,"sixtyDayClose":14.56},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX.AU\",params:#limit:5,,,undefined,":[{"date":"2026-08-20","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787184000000,"name":null,"time":"","dateTimestamp":1787148000000,"actualEps":null},{"date":"2026-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1771455600000,"name":null,"time":"","dateTimestamp":1771419600000,"actualEps":null},{"date":"2026-01-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1768777200000,"name":null,"time":"","dateTimestamp":1768741200000,"actualEps":null},{"date":"2025-08-21","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755734400000,"name":null,"time":"","dateTimestamp":1755698400000,"actualEps":null},{"date":"2025-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1739919600000,"name":null,"time":"","dateTimestamp":1739883600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLX.AU\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2627242762","title":"Telix Pharmaceuticals Ltd - Telix Successfully Prices Upsized US$600M Convertible Bonds","url":"https://stock-news.laohu8.com/highlight/detail?id=2627242762","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627242762?lang=en_us&edition=fundamental","pubTime":"2026-04-15 06:14","pubTimestamp":1776204873,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nFWN40X1BN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627441049","title":"Telix Pharmaceuticals Ltd -  Upsizes Convertible Notes Due 2031 to US$600 Milion - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2627441049","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627441049?lang=en_us&edition=fundamental","pubTime":"2026-04-14 21:34","pubTimestamp":1776173680,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nFWN40X0A8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627445663","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2627445663","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627445663?lang=en_us&edition=fundamental","pubTime":"2026-04-14 20:01","pubTimestamp":1776168074,"startTime":"0","endTime":"0","summary":"T1 Energy  shares were 5.7% lower in Tuesday's premarket activity after the company said it is proposing an underwritten public offering of $125 million in convertible senior notes due 2031.CarMax  shares were down 4.2% after the company reported lower fiscal Q4 adjusted earnings and net sales and operating revenue from a year earlier.Telix Pharmaceuticals  stock was 5.1% lower after the company said it commenced a $550 million offering of convertible notes due 2031.Wells Fargo  shares were down 2.4% after the Wall Street bank reported lower-than-expected Q1 revenue.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0029864427.USD","LU1668664300.SGD","LU1894683348.USD","LU1814569148.SGD","LU0106831901.USD","LU0251142724.SGD","LU1267930573.SGD","LU0208291251.USD","LU0310800379.SGD","BK4588","LU0175139822.USD","LU0314106906.USD","TE","IE00B7SZLL34.SGD","BK4207","LU0048573561.USD","TLX","BK4096","BK4559","LU0640476718.USD","LU1363072403.SGD","LU0477156953.USD","IE0002270589.USD","BK4504","LU1069347547.HKD","LU1035773651.USD","LU1791807156.HKD","LU0310799852.SGD","KMX","LU0211327993.USD","LU0787776722.HKD","LU0417517546.SGD","IE000M9KFDE8.USD","TLX.AU","LU2236285917.USD","LU0154236417.USD","LU2361044865.SGD","LU0683600562.USD","LU0942090050.USD","LU1267930227.SGD","BK4585","LU0130102774.USD","LU0149725797.USD","LU0251131958.USD","BK4139","LU0971096721.USD","IE00B19Z3B42.SGD","LU1506573853.SGD","LU1074936037.SGD","LU2361045086.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627448835","title":"BRIEF-Telix Pharmaceuticals Launches Offering Of $550 MLN Convertible Notes Due 2031 To Be Issued By Its Unit","url":"https://stock-news.laohu8.com/highlight/detail?id=2627448835","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627448835?lang=en_us&edition=fundamental","pubTime":"2026-04-14 19:06","pubTimestamp":1776164800,"startTime":"0","endTime":"0","summary":"BRIEF-Telix Pharmaceuticals Launches Offering Of $550 MLN Convertible Notes Due 2031 To Be Issued By Its UnitApril 14  - Telix Pharmaceuticals Ltd TLX.AX:TELIX REFINANCES CONVERTIBLE BONDSLAUNCHES AN OFFERING OF US$550 MILLION CONVERTIBLE NOTES DUE 2031 TO BE ISSUED BY ITS WHOLLY-OWNED SUBSIDIARYINITIAL CONVERSION PRICE WILL BE AT A PREMIUM TO TELIX'S CURRENT SHARE PRICE.INTENDED THAT NET PROCEEDS TO BE USED TO REPURCHASE EXISTING CONVERTIBLE BONDS DUE 2029Further company coverage: TLX.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nFWN40W102:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627416477","title":"Telix launches US$550 million convertible notes offering due 2031","url":"https://stock-news.laohu8.com/highlight/detail?id=2627416477","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627416477?lang=en_us&edition=fundamental","pubTime":"2026-04-14 16:36","pubTimestamp":1776155793,"startTime":"0","endTime":"0","summary":"Telix launched offering of US$ 550 million convertible notes due 2031.Net proceeds earmarked for repurchase of existing convertible bonds due 2029.Bookbuild set to determine final terms before market open April 15, 2026.Notes marketed with coupon or yield guidance of 1.5%-1.75%.Conversion premium guided at 35%-37.5% to reference share price set via concurrent delta placement.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nNDLn07nW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627416002","title":"Telix Refinances Convertible Bonds","url":"https://stock-news.laohu8.com/highlight/detail?id=2627416002","media":"prnewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627416002?lang=en_us&edition=fundamental","pubTime":"2026-04-14 16:32","pubTimestamp":1776155520,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, Ind., April 14, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited   today launches an offering of US$550 million convertible notes due 2031 to be issued by its wholly-owned subsidiary, Telix Pharmaceuticals  Inc. , and guaranteed by Telix and Telix Pharmaceuticals  Inc. . The convertible notes, also referred to as \"convertible bonds\" , are convertible into fully paid ordinary shares in Telix .Managing Director and Group CEO, Dr. Christian Behrenbruch, said: \"The refinance of the existing Convertible Bonds represents our proactive approach to capital management. The new Convertible Bonds will continue to provide the business with cost effective financing.\". The new Convertible Bonds represent attractive, low-cost financing to Telix and are non-dilutive until any potential future conversions occur. The initial conversion price will be at a premium to Telix's current share price.After deduction of commissions, professional fees and other administrat","market":"fut","thumbnail":"https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/telix-refinances-convertible-bonds-302741509.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4543","BK7039","ASX","SEC.AU","BK4526","BK4141","ASX.AU","BK7067","TLX","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627949068","title":"Telix Pharmaceuticals Ltd - Launches an Offering of US$550 Mln Convertible Notes Due 2031 to Be Issued by Its Wholly-Owned Subsidiary","url":"https://stock-news.laohu8.com/highlight/detail?id=2627949068","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627949068?lang=en_us&edition=fundamental","pubTime":"2026-04-14 14:54","pubTimestamp":1776149677,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nFWN40W102:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627490622","title":"Telix Pharmaceuticals Ltd - Initial Conversion Price Will Be at a Premium to Telix's Current Share Price.","url":"https://stock-news.laohu8.com/highlight/detail?id=2627490622","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627490622?lang=en_us&edition=fundamental","pubTime":"2026-04-14 14:54","pubTimestamp":1776149677,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nFWN40W102:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627897434","title":"Regeneron Pharmaceuticals Inc - Telix Will Receive an Upfront Cash Payment of US$40 Mln From Regeneron","url":"https://stock-news.laohu8.com/highlight/detail?id=2627897434","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627897434?lang=en_us&edition=fundamental","pubTime":"2026-04-13 18:30","pubTimestamp":1776076200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nTUACB1KYL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0053666078.USD","LU0320765992.SGD","LU0823416689.USD","BK4585","LU0109394709.USD","LU0058720904.USD","LU2362541513.USD","LU2106854487.HKD","LU0882574055.USD","BK4139","TLX.AU","LU1917777945.USD","BK7067","LU0289739699.SGD","LU0823434740.USD","LU1974910355.USD","LU2362540622.SGD","LU0114720955.EUR","LU0823434583.USD","LU0889565916.HKD","LU2362541273.HKD","BK4588","LU2023250504.SGD","REGN","LU2468319806.SGD","LU2089984988.USD","LU2237438978.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627483320","title":"BUZZ-Australia's Telix Pharmaceuticals rises on $40 mln Regeneron deal; Citi sees 'broader' scope","url":"https://stock-news.laohu8.com/highlight/detail?id=2627483320","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627483320?lang=en_us&edition=fundamental","pubTime":"2026-04-13 10:38","pubTimestamp":1776047920,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Telix Pharmaceuticals rises on $40 mln Regeneron deal; Citi sees 'broader' scope** Telix Pharmaceuticals TLX.AX rises as much as 8.8% to A$15.93, highest since November 5, 2025** Stoc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nL6N40W05T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067","LU0889565916.HKD","LU0823434740.USD","LU0320765992.SGD","REGN","LU0289739699.SGD","LU1917777945.USD","LU2023250504.SGD","LU0114720955.EUR","LU2237438978.USD","LU0882574055.USD","LU0109394709.USD","BK4139","LU2362541513.USD","LU1974910355.USD","LU2362541273.HKD","BK4585","BK4588","LU2089984988.USD","LU0823434583.USD","LU2468319806.SGD","LU2362540622.SGD","LU0053666078.USD","LU0058720904.USD","LU2106854487.HKD","LU0823416689.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158547007","title":"Stock Track | Telix Pharmaceuticals Soars 7.58% Intraday on Major Regeneron Collaboration Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=1158547007","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158547007?lang=en_us&edition=fundamental","pubTime":"2026-04-13 08:04","pubTimestamp":1776038653,"startTime":"0","endTime":"0","summary":"TELIX PHARMACEUTICALS LTD (TLX.AU) saw its stock price soar 7.58% during intraday trading on Monday, following a significant corporate announcement.The sharp increase is attributed to the company's...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627101920","title":"Telix and Regeneron Announce Strategic Radiopharma Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2627101920","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627101920?lang=en_us&edition=fundamental","pubTime":"2026-04-13 06:57","pubTimestamp":1776034620,"startTime":"0","endTime":"0","summary":"Telix to receive US$40 million upfront for four initial programs with optionality on a per program basis to co-fund commercialization and profit-share or earnup to an aggregate of US$2.1 billion in developmentand commercial milestone payments pluslow double-digit royalties.","market":"nz","thumbnail":"https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/telix-and-regeneron-announce-strategic-radiopharma-collaboration-302739967.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089984988.USD","LU2468319806.SGD","ASX.AU","LU0882574055.USD","LU2237438978.USD","LU2362541273.HKD","LU0058720904.USD","BK4526","LU0823434740.USD","REGN","BK4141","LU0320765992.SGD","BK4543","LU0823416689.USD","ASX","TLX","SEC.AU","LU0053666078.USD","LU0823434583.USD","LU0109394709.USD","LU0114720955.EUR","LU0889565916.HKD","LU1974910355.USD","LU2106854487.HKD","BK4585","LU2362541513.USD","LU0289739699.SGD","BK7039","BK4139","BK7067","LU2023250504.SGD","LU2362540622.SGD","BK4588","LU1917777945.USD","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627888101","title":"Telix Pharmaceuticals Ltd - to Receive $40 Mln Upfront and up to $2.1 Bln in Milestones Plus Royalties","url":"https://stock-news.laohu8.com/highlight/detail?id=2627888101","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627888101?lang=en_us&edition=fundamental","pubTime":"2026-04-13 06:28","pubTimestamp":1776032882,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260412:nTUE9FVW25:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1974910355.USD","LU0823434583.USD","LU0320765992.SGD","BK4588","LU2106854487.HKD","BK4585","LU2362541273.HKD","LU0053666078.USD","LU0823416689.USD","LU0882574055.USD","LU2089984988.USD","LU0289739699.SGD","LU2362541513.USD","LU1917777945.USD","LU0109394709.USD","LU0889565916.HKD","TLX.AU","LU2023250504.SGD","LU0058720904.USD","LU0823434740.USD","LU0114720955.EUR","BK7067","LU2468319806.SGD","REGN","LU2362540622.SGD","LU2237438978.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627710900","title":"Telix Pharmaceuticals Ltd-Telix and Regeneron Announce Radiopharma Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2627710900","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627710900?lang=en_us&edition=fundamental","pubTime":"2026-04-13 06:28","pubTimestamp":1776032882,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260412:nTUE9FVW25:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626118762","title":"Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Amid Lingering Geopolitical Uncertainty, CPI Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2626118762","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626118762?lang=en_us&edition=fundamental","pubTime":"2026-04-10 21:15","pubTimestamp":1775826917,"startTime":"0","endTime":"0","summary":"The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.1% and the actively traded Invesco QQQ Trust (QQQ) was 0.1% higher in Friday's premarket activity amid lingering geopolitica","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XLI","RTH","BITO","SLV","XSD","TLX","EXI","XLK","VIS","IYK","SOXX","VHT","XLV","EEM","IYH","QQQ","NMG","E","XRT","FAS","EETH","SLM.AU","IGM","VDC","FDN","BETH","XLP","EQR","IBB","IYE","NMG.AU","USO","SPY","IVV","TSM","IYW","XLY","FAZ","IYJ","SHAK","RTH.AU","XLE","AOS","GLD","SPY.AU","TLX.AU","XLF","SLM","VHT.AU","UNG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626151448","title":"BUZZ-Australia's Telix Pharmaceuticals rises as US FDA approves drug application","url":"https://stock-news.laohu8.com/highlight/detail?id=2626151448","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626151448?lang=en_us&edition=fundamental","pubTime":"2026-04-10 08:43","pubTimestamp":1775781831,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Telix Pharmaceuticals rises as US FDA approves drug application** Telix Pharmaceuticals TLX.AX rises as much as 8.4% to A$14.79, highest since December 8** Co says U.S. FDA accepts resubmitted New Drug Application for TLX101-Px** TLX101-Px is an investigational Positron emission tomography agent for imaging of glioma ** YTD, TLX up 26.3%  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nL4N40T011:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194270889","title":"Stock Track | Telix Pharmaceuticals Soars 8.14% Intraday on FDA Acceptance of Brain Cancer Imaging Agent NDA","url":"https://stock-news.laohu8.com/highlight/detail?id=1194270889","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194270889?lang=en_us&edition=fundamental","pubTime":"2026-04-10 08:02","pubTimestamp":1775779363,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) saw its shares surge 8.14% during intraday trading on Friday, following a significant regulatory development for one of its key investigational...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626126156","title":"Telix Pharmaceuticals Says US FDA Accepts New Drug Application for Brain Cancer Imaging Agent","url":"https://stock-news.laohu8.com/highlight/detail?id=2626126156","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626126156?lang=en_us&edition=fundamental","pubTime":"2026-04-10 07:25","pubTimestamp":1775777139,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  said the US Food and Drug Administration  has accepted its resubmitted new drug application for TLX101-Px, an investigational positron emission tomography  agent for the imaging of glioma, a form of brain cancer, according to a Friday filing with the Australian bourse.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX","BK4588","BK4139","TLX.AU","LABU","BK7067","BK7047","PET.AU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626815689","title":"FDA Accepts Nda for Tlx101-Px (Pixclara®)","url":"https://stock-news.laohu8.com/highlight/detail?id=2626815689","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626815689?lang=en_us&edition=fundamental","pubTime":"2026-04-10 06:51","pubTimestamp":1775775089,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nTUARRPF8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626156814","title":"FDA Accepts NDA for TLX101-Px (Pixclara®)","url":"https://stock-news.laohu8.com/highlight/detail?id=2626156814","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626156814?lang=en_us&edition=fundamental","pubTime":"2026-04-10 06:50","pubTimestamp":1775775000,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, April 10, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited  today announces that the United States  Food and Drug Administration  has accepted the Company's resubmitted New Drug Application  for TLX101-Px[1], , an investigational PET[3] agent for the imaging of glioma , and has assigned a PDUFA[4] goal date of September 11, 2026.The approval of TLX101-Px will fulfil a significant unmet medical need for the characterization of recurrent or progressive glioma from treatment related changes in both adult and pediatric patients[5]. Neuroimaging of glioma with 18F-FET is already broadly recommended in international clinical practice guidelines – including NCCN Guidelines[6] – and TLX101-Px has been granted Orphan Drug[7] and Fast Track[8] designations by the FDA.Patrick Wen, MD, E. Antonio Chiocca,MD, PhD, Family Endowed Chair in Neuro-Oncology at Mass General Brigham Cancer Institute, added, \"Distinguishing tumor progression from treatment-related c","market":"nz","thumbnail":"https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/fda-accepts-nda-for-tlx101-px-pixclara-302738824.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","BK4526","BK4135","BK7039","BK7104","BK4585","LABU","CNS","SEC.AU","TLX.AU","BK4141","GBM.AU","BK7067","BK4543","ASX","TLX","ASX.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":198,"code":"91000000","status":"200"}]}}